Savara
IPOBreathing new life into rare respiratory disease treatment
Public · Austin, United States · Founded 2008 · $17.4M raised
- Headquarters
- Austin, Texas
- Employees
- 51–200
- Founded
- 2008
- Business Model
- B2B
- Website
- savarapharma.com
- Total Funding
- $17.4M
- Last Round
- $7.4M Series BMar 2013
- Rounds
- 3
- Type
- Public
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Savara Inc. (Nasdaq: SVRA) is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its lead product candidate, molgramostim inhalation solution (MOLBREEVI), is an inhaled recombinant GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease causing progressive respiratory failure.
Summary
Savara is a Biotech company based in Austin, United States, founded in 2008. It has raised $17.4M in total across 3 rounds, most recently a $7.4M Series B round in Mar 2013. Investors include RTW Investments.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding & Exit History
Oct 2025
Sign up to see all 9 events
Funding: Series B. Amounts, valuations, and investors where available.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Integrated biopharmaceutical solutions company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/savara"><img src="https://indexed.vc/api/badge/company/savara" alt="Savara on Indexed.vc" width="260" height="76" /></a>